trending Market Intelligence /marketintelligence/en/news-insights/trending/eaPdOTnPm73ic6iOaFy5Zw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Portola Pharmaceuticals plans $200M common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Portola Pharmaceuticals plans $200M common stock offering

Portola Pharmaceuticals Inc. is planning an underwritten public offering of $200 million of its common shares.

Goldman Sachs & Co. LLC, Citigroup, Cowen, and William Blair are acting as joint book-running manager in the offering, with Oppenheimer & Co. Inc. as lead manager. The underwriters will be granted an option to buy up to an additional $30 million common shares in the transaction.

South San Francisco, Calif.-based Portola Pharmaceuticals is developing therapies for serious blood-related disorders.